OverviewSuggest Edit

Mereo is a biopharma company with a focus on developing products for orphan and rare diseases acquired from large pharma companies. The Company has acquired an initial mid-late stage portfolio of three exceptionally well characterized novel products for the treatment of diseases with considerable unmet medical need from Novartis Pharmaceuticals. Each of these programmes has a comprehensive dataset for both pre-clinical and proof-of-concept clinical studies. Additional product opportunities are under evaluation.

Mereo's focus is the development of innovative medicines that have the potential to significantly transform the lives of patients suffering from rare and other specialised conditions around the world. To do this, the Company depends on the combination of its team's expertise in selecting and acquiring product opportunities, creating value in the development pipeline and structuring creative transactions. Mereo's internal expertise is complemented by a unique partnership with a leading global CRO, ICON.

TypePublic
Founded2015
HQGreater London, GB
Websitemereobiopharma.com

Latest Updates

Employees (est.) (Dec 2020)50
Share Price (Dec 2020)£0.3(-1%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Mereo BioPharma

Denise Scots-Knight

Denise Scots-Knight

Chief Executive Officer, Board Member
Peter Fellner

Peter Fellner

Chairman
Christine Fox

Christine Fox

Chief Financial Officer
Anders Ekblom

Anders Ekblom

Board Member
Charles Sermon

Charles Sermon

General Counsel
Alastair MacKinnon

Alastair MacKinnon

Chief Portfolio Management and Pipeline Strategy
Show more

Mereo BioPharma Office Locations

Mereo BioPharma has an office in Greater London
Greater London, GB (HQ)
1 Cavendish Pl
Show all (1)

Mereo BioPharma Financials and Metrics

Mereo BioPharma Revenue

Market capitalization (17-Dec-2020)

89.8m

Closing stock price (17-Dec-2020)

0.3

Cash (31-Dec-2018)

25.0m

EV

86.2m
Mereo BioPharma's current market capitalization is £89.8 m.
GBPFY, 2016FY, 2017FY, 2018

Cash

53.6m50.0m25.0m

Accounts Receivable

293.3k293.3k

Current Assets

60.8m63.2m34.5m
GBPFY, 2016FY, 2017FY, 2018

Cash From Operating Activities

(29.7m)(32.1m)(23.1m)

Cash From Investing Activities

372.6k(3.7m)251.6k

Cash From Financing Activities

68.4m33.7m(2.1m)

Net Change in Cash

39.1m(2.1m)(25.0m)
FY, 2016

Financial Leverage

1.1 x
Show all financial metrics

Mereo BioPharma Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

Mereo BioPharma Online and Social Media Presence

Embed Graph

Mereo BioPharma News and Updates

Mereo BioPharma Announces Appointment of Pierre Jacquet, M.D., Ph.D. to Board of Directors

LONDON and REDWOOD CITY, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Pierre Jacquet, M.D., Ph.D to the Company’s B…

Mereo BioPharma to Participate in Three Upcoming Investor Conferences

LONDON and REDWOOD CITY, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced senior management’s participation in three upcoming investor co…

Mereo BioPharma to Participate in a Fireside Chat at the BTIG Virtual Biotechnology Conference

LONDON and REDWOOD CITY, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo, …

Thinking about buying stock in Mereo BioPharma, Lipocine, Lordstown Motors, Sorrento Therapeutics, or Axcella Health?

NEW YORK, June 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MREO, LPCN, RIDE, SRNE, and AXLA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Mereo BioPharma Announces Positive Desmosine Biomarker Data from an Interim Analysis of an Investigator Initiated Study of alvelestat in Bronchiolitis Obliterans Syndrome (BOS)

LONDON and REDWOOD CITY, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced positive data from an interim analysis of an investigator-initia…

Mereo BioPharma to Participate in a Fireside Chat at the Jefferies 2021 Virtual Healthcare Conference

LONDON and REDWOOD CITY, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo, w…
Show more

Mereo BioPharma Frequently Asked Questions

  • When was Mereo BioPharma founded?

    Mereo BioPharma was founded in 2015.

  • Who are Mereo BioPharma key executives?

    Mereo BioPharma's key executives are Denise Scots-Knight, Peter Fellner and Christine Fox.

  • How many employees does Mereo BioPharma have?

    Mereo BioPharma has 50 employees.

  • Who are Mereo BioPharma competitors?

    Competitors of Mereo BioPharma include Alembic Pharmaceuticals, EMS Pharma and Livzon Pharmaceutical Group.

  • Where is Mereo BioPharma headquarters?

    Mereo BioPharma headquarters is located at 1 Cavendish Pl, Greater London.

  • Where are Mereo BioPharma offices?

    Mereo BioPharma has an office in Greater London.

  • How many offices does Mereo BioPharma have?

    Mereo BioPharma has 1 office.